Collectively, these data indicate that CTCF and EGR1 act as transcription factors to drive Nm23-H1 expression in less metastatic breast cancer cells, whereas their lower expression in aggressive breast cancers may contribute to reduced levels of Nm23-H1. Here, CTCF is linked to breast carcinoma.